Portal Biotechnologies Raises $9M To Scale Platform

Portal Biotechnologies, announced updates on significant commercial progress and the closing of an oversubscribed $9M financing round led by NFX and participation from existing backers including IA Ventures, Pear VC, Undeterred Ventures, IKJ Capital, and TechU.

Portal is building the universal infrastructure for cell engineering across drug discovery and cell therapy. The proprietary platform leverages mechanoporation to enable efficient, scalable delivery of RNA, gene editors, probes, and other molecules into hard-to-transfect cells across many cell types and workflows.

The capital will accelerate commercial scaling of Portal's platform, which solves one of biology's ultimate bottlenecks: delivering a broad range of complex molecules safely and efficiently inside cells without compromising their function.

Portal’s expansion efforts are focused on three key areas:

● Novel drug discovery workflows

● Cost-effective multi-perturbation AI data generation

● Next-gen cell therapies with our academic and biopharma partners

"Portal is achieving what very few biotech platforms manage in their first 3 years: meaningful commercial revenue, technical validation from the world's largest companies, and a genuinely game-changing vision," said Omri Amirav-Drory, Ph.D., General Partner at NFX Bio. "With an elegant, scalable engineering platform, Portal is perfectly positioned to underpin future drug discovery, techbio, and cell therapy ecosystems. We are thrilled to lead this round and back the Portal team."

Since its launch, Portal's proprietary mechanoporation technology has seen rapid adoption by top pharma, AI x Bio tech giants, and world-renowned academic centers. Recent highlights include:

● Rethinking Drug Discovery: Researchers at Merck, AbbVie, and Purdue have presented novel applications ranging from screening impermeable degraders and peptide molecules to novel DEL and target-engagement assays. Multiple pharma customers have upgraded to the high-throughput Galaxy-i platform since its launch earlier this year.

● Generating Rich Biological Data for AI: The Ragon Institute of Harvard/MIT/MGB and Microsoft have committed to a two-year project using Portal to generate model training data and map immune responses at scale. Additional collaborations in multi-perturbation screens are also underway.

● Advancing Next-Generation Cell Therapy at the Point of Care: DARPA expanded its initial $8M contract to develop a portable, field-deployable device for rapid point-of-care cell therapy production, and is now supporting commercialization through its EEI program. Mass General Brigham also recently presented at ASGCT on the use of Portal's platform for same-day, circRNA-based multifunctional CAR-T production.

This article has been republished from external sources. Note: Material may have been edited for clarity, length, or style. For more information, please contact the cited source.